Abstract:Background: Common genetic variation explains up to 40% of blood pressure variation. Despite this compelling physiological impact, the role of common genetic variation in blood pressure treatment and their sequelae remains understudied. We hypothesize that a higher polygenic predisposition to hypertension leads to a poorer response to blood pressure (BP) treatment and higher stroke risk in a primary prevention setting. Methods: We conducted a 2-stage genetic association study using data from the All of Us Research Program (discovery stage) and UK Biobank (replication stage). We included participants on any BP medication at enrollment and excluded those with prior stroke. Participants were categorized as having low, intermediate, or high polygenic predisposition to hypertension according to percentiles ( 80) of a polygenic risk score of 177 independent risk variants. Uncontrolled systolic BP was defined as >140mmHg and incident stroke was ascertained using Electronic Health Record data and ICD 9/10 codes. We used multivariate logistic and Cox Proportional Hazards regressions, as appropriate, to assess the relationship between genetic predisposition to hypertension and both uncontrolled BP and incident stroke. Results: The discovery stage included 110,892 participants (mean age 58, female sex 58%). Compared to low polygenic risk, intermediate and high risk were linked with 14% (OR 1.14, 95%CI 1.10-1.18) and 30% (OR 1.30, 95%CI 1.24-1.36) surge of uncontrolled BP risk (p<0.001). Similarly, compared to low polygenic risk, intermediate and high risk were associated with 8% (HR 1.08, 95%CI 0.97-1.20) and 15% (HR 1.15, 95%CI 1.00-1.30) increments in stroke risk (p=0.04). These results were replicated in 102,252 participants (mean age 61, female sex 47%) enrolled in the UK Biobank (p<0.05 for both analyses). Conclusions: Among participants on antihypertensive medications, increased genetic predisposition to hypertension correlated with higher risk of uncontrolled BP and stroke. As All of Us and direct-to-consumer companies return genomic information to millions of Americans, our findings support further research, including clinical trials, to explore personalized treatments targeting high-risk subjects for intense interventions.

Progress in search for influence the factors of metoprolol on pharmacokinetics and pharmacodynamics

Electrocardiographic left ventricular hypertrophy, β3 adrenergic receptor polymorphism and endpoint of ACEI treatment of hypertension

Hypertensive Patients from Two Rural Chinese Counties Respond Differently to Benazepril: the Anhui Hypertension Health Care Study

Identifying drug-related attributes to personalise antihypertensive agents: the outcome report of patients receiving metoprolol therapy

Pharmacokinetics and pharmacodynamics characterization of subjects with novel CYP2D6 genotypes using probe drug metoprolol

Influence of multiple risk factor control level on cardiovascular outcomes in hypertensive patients

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients

Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoreceptor blocking properties

Characterizing the Critical Features when Personalizing Antihypertensive Drugs Using Spectrum Analysis and Machine Learning Methods.

The Effect of Metoprolol on Neuroendocrine Activities and Cardiac Function in Patients with Congestive Heart Failure

Abstract 8: Polygenic Resistance to Blood Pressure Treatment and Stroke Risk

Influence of metformin on blood pressure and metabolism in 155 patients with obesity hypertensives

Study on Genotype and Phenotype of Novel CYP2D6 Variants Using Pharmacokinetic and Pharmacodynamic Models with Metoprolol As a Substrate Drug

Benefits of Antihypertensive Pharmacologic Therapy and Blood Pressure Reduction in Outcome Trials

Effect Of Metoprolol Succinate In Patients With Stable Angina And Elevated Heart Rate Receiving Low-Dose Beta-Blocker Therapy

Β2adrenergic Receptor GeneArg16GlyPolymorphism is Associated with Therapeutic Efficacy of Benazepril on Essential Hypertension in Chinese

Pharmacogenomics assists in controlling blood pressure in cardiovascular and cerebrovascular patients during Rehabilitation: a case report

Mathematical modeling of the influence of polymorphism on blood pressure and antihypertensive therapy

GW26-e0732 Superior Dynamic Heart Rate Control and Non-Inferior Blood Pressure Control with Bisoprolol Vs Metoprolol Sustained Release Tablet in Mild-to-Moderate Hypertension: CREATIVE Study

What Can Be Expected from Optimal Blood Pressure Control?

Blood pressure lowering and stroke prevention: a systematic review and network meta-analysis protocol.